- Active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
This study is looking at a new drug called JNJ-63723283 for people with advanced cancers. It aims to find the right dose and see how well it works. This drug is designed to help the body's immune system fight cancer.
For: NeoplasmsUnited States · Moldova · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
This study is testing new treatments for bladder cancer that has grown into the muscle. It looks at a new drug delivery system, TAR-200, with or without another drug called cetrelimab, before surgery. The aim is to see how well these treatments shrink the cancer or make it disappear.
For: Muscle-Invasive Urothelial Carcinoma of the BladderGermany · Netherlands · Spain